Anti-CD3 × anti-HER2 bispecific antibody armed activated T cell

Anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (commonly referred to as HER2 BATs or HER2Bi-armed ATCs) are a form of adoptive cell therapy in which ex vivo expanded and activated human T cells are coated with a chemically conjugated bispecific antibody that targets both CD3 (on the surface of all T cells) and the human epidermal growth factor receptor 2 (HER2), which is overexpressed in various cancers. This arming process redirects the cytotoxic activity of polyclonal activated T cells specifically toward tumor cells expressing high or low levels of HER2. The mechanism involves non-MHC restricted killing via perforin and granzyme B release. These therapies have been investigated primarily for metastatic breast cancer—including both hormone receptor positive/HER2-negative and triple negative subtypes—as immune consolidation after chemotherapy, but also show preclinical efficacy against other solid tumors such as prostate cancer and colorectal carcinoma[1][3][5][6][8]. The approach aims to overcome limitations seen with monoclonal antibodies or unarmed bispecific antibodies by combining direct cytotoxicity with targeted immune redirection.

Other names

anti-CD3 x anti-HER2 BiAb armed ATCanti-CD-3 x anti-HER2 BiAb armed ATCanti-CD 3 x anti-HER2 BiAb armed ATCbispecific anti‑CD3 x anti‑HER2 antibody armed activated T cells